key: cord-0941293-0rpbl2os authors: Fontana, Igor C.; Souza, Débora Guerini; Pellerin, Luc; Souza, Diogo O.; Zimmer, Eduardo R. title: About the source and consequences of (18)F-FDG brain PET hypometabolism in short and long COVID-19 date: 2021-04-04 journal: Eur J Nucl Med Mol Imaging DOI: 10.1007/s00259-021-05342-y sha: f862f85e0e55e89e9d1a366cd49904e90c147f2b doc_id: 941293 cord_uid: 0rpbl2os nan In 1977, Sokoloff developed and validated a kinetic model for estimating brain glucose metabolism using PET 18 F-FDG [5] . Sokoloff's two-tissue compartment model comprises 18 F-FDG in plasma, free 18 F-FDG and phosphorylated 18 F-FDG in brain tissue [5] . For more than 4 decades, the biological interpretation of brain PET 18 F-FDG signal was considered a direct index of neuronal activity [6] . Nevertheless, over the last years, a more integrative view in which astrocytes, an abundant type of glial cells, are also prominent contributors to the 18 F-FDG PET signal has emerged [7] . Indeed, it seems that astrocytes substantially contribute to 18 F-FDG PET signal [8] [9] [10] . Moreover, it is known that astrocytes play pivotal roles in the brain defence against peripheral inflammatory changes [11] . Guedj and colleagues [1] mentioned that acute systemic inflammation and SARS-CoV-2 neurotropism could be related to brain inflammatory alterations. Complementary, other groups identified signs of reactive astrogliosis in postmortem tissue of COVID-19 patients [12] , in cellular models and in brain organoids [13] . In keeping with this, one could not neglect astrocyte dysfunction as the possible cellular origin of brain 18 F-FDG PET hypometabolism in COVID-19. In vivo brain imaging of COVID-19 individuals using specific PET radiotracers targeting reactive astrocytes (e.g. 11 C-DED and 11 C-BU99008) could help settling this matter. Persistent brain hypometabolism measured by 18 F-FDG PET -a risk for developing neurodegenerative diseases While the cellular origins of brain 1 8 F-FDG PET hypometabolism in COVID-19 remain to be defined, it seems clear that we are dealing with persistent synaptic dysfunction. Guedj et al. [1] demonstrated that multiple brain regions are hypometabolic in long COVID. In addition, it seems that there This article is part of the Topical Collection on Letter to the Editor * Eduardo R. Zimmer eduardo.zimmer@ufrgs.br 1 is a link between clinical manifestations and regional glucose hypometabolism. For instance, decreased glucose consumption in the cerebellum was linked to hyposmia/anosmia and cognitive impairment. Another recent study followed up the 18 F-FDG brain profile of seven patients in the early phase of infection, 1 month and 6 months after COVID-19 onset. Interestingly, the abnormal cognitive function associated with pre-frontal cortex hypometabolism persisted in all patients for 6 months [14] . Remarkably, 18 F-FDG brain hypometabolism in the pre-frontal cortex is present in multiple neurodegenerative disorders [15] and neuropsychiatric conditions [16] , sometimes even preceding the first symptoms. Thus, the cellular origins of COVID-19 18 F-FDG PET hypometabolism in short-and long-term scenario remain to be explored, with mounting evidence suggesting an astroglial contribution. Furthermore, persistent 18 F-FDG PET hypometabolism in long COVID patients should be carefully monitored in terms of potential sequelae, such as the development of brain disorders. )F-FDG brain PET hypometabolism in patients with long COVID PET imaging as a tool for assessing COVID-19 brain changes Covid-19-related encephalopathy: a case series with brain FDG-PET/CT findings 18) FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19 The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies 18)F]FDG PET signal is driven by astroglial glutamate transport Astrocyte biomarkers in Alzheimer's disease Glucose utilization: still in the synapse Astrocyte barriers to neurotoxic inflammation Neuropathology of patients with COVID-19 in Germany: a post-mortem case series ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia Conflict of interest The authors declare no competing interests.